Literature DB >> 6245355

Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states.

Y I Kim, M M Goldner, D B Sanders.   

Abstract

The in vitro effects of 4-aminopyridine (4-AP) on neuromuscular transmission were determined by microelectrode techniques in intercostal muscles from patients with myasthenia gravis (MG) and the Eaton-Lambert syndrome (ELS), and in forelimb muscles from rats with experimental autoimmune myasthenia gravis (EAMG). In MG and EAMG, the amplitudes of miniature endplate potentials (MEPPs) and endplate potentials (EPPs) were reduced, and there was increased sensitivity to the blocking action of d-tubocurarine (dTc). In ELS, MEPP amplitude was normal but the average number of acetylcholine quanta released by nerve impulses was reduced, causing subthreshold EPPs. In EAMG muscle, 4-AP produced dose-dependent increases in EPP amplitude and in the duration of indirectly elicited muscle action potentials but no changes in MEPP amplitude and resting membrane potential. 4-AP completely reversed the postsynaptic blockade produced by dTc and EAMG. 4-AP appears to facilitate neuromuscular transmission in EAMG, MG, and ELS by increasing the neurally evoked transmitter release, thus overcoming either the pre- or the postsynaptic neuromuscular blockade.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6245355     DOI: 10.1002/mus.880030203

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Clinically Relevant Levels of 4-Aminopyridine Strengthen Physiological Responses in Intact Motor Circuits in Rats, Especially After Pyramidal Tract Injury.

Authors:  Anil Sindhurakar; Asht M Mishra; Disha Gupta; Jennifer F Iaci; Tom J Parry; Jason B Carmel
Journal:  Neurorehabil Neural Repair       Date:  2017-01-20       Impact factor: 3.919

2.  Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine.

Authors:  D B Sanders; Y I Kim; J F Howard; C A Goetsch
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

3.  Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

4.  Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs.

Authors:  Mario Losen; Pilar Martinez-Martinez; Peter C Molenaar; Konstantinos Lazaridis; Socrates Tzartos; Talma Brenner; Rui-Sheng Duan; Jie Luo; Jon Lindstrom; Linda Kusner
Journal:  Exp Neurol       Date:  2015-03-18       Impact factor: 5.330

5.  Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Authors:  Kawita M S Kanhai; Jenny A Nij Bijvank; Yorick L Wagenaar; Erica S Klaassen; KyoungSoo Lim; Sandrin C Bergheanu; Axel Petzold; Ajay Verma; Jacob Hesterman; Mike P Wattjes; Bernard M J Uitdehaag; Laurentius J van Rijn; Geert Jan Groeneveld
Journal:  CNS Neurosci Ther       Date:  2019-02-12       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.